Published in J Hepatol on February 01, 2005
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology (2010) 2.47
Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study. Am J Epidemiol (2013) 2.44
Varenicline reduces alcohol self-administration in heavy-drinking smokers. Biol Psychiatry (2009) 2.25
Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. BMJ (2010) 2.24
Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases. Free Radic Biol Med (2008) 2.14
Heavy smoking and liver. World J Gastroenterol (2006) 1.33
Targeted therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2009) 1.27
Epidemiology of primary and secondary liver cancers. Semin Intervent Radiol (2006) 1.25
2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma. Gut Liver (2015) 1.23
Clearing the smoke in chronic liver diseases. Hepatology (2010) 1.17
Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: case-control study. Int J Cancer (2008) 1.16
Smoking, obesity, and their co-occurrence in the United States: cross sectional analysis. BMJ (2006) 1.16
2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma. Korean J Radiol (2015) 1.14
Pathways between socioeconomic status and modifiable risk factors among African American smokers. J Behav Med (2009) 1.08
Multicausality in fatty liver disease: is there a rationale to distinguish between alcoholic and non-alcoholic origin? World J Gastroenterol (2012) 1.05
Emerging role of redox dysregulation in alcoholic and nonalcoholic fatty liver disease. Antioxid Redox Signal (2011) 1.05
Socioeconomic status, negative affect, and modifiable cancer risk factors in African-American smokers. Cancer Epidemiol Biomarkers Prev (2008) 1.04
National record linkage study of mortality for a large cohort of opioid users ascertained by drug treatment or criminal justice sources in England, 2005-2009. Drug Alcohol Depend (2014) 1.02
Ethanol and tobacco smoke increase hepatic steatosis and hypoxia in the hypercholesterolemic apoE(-/-) mouse: implications for a "multihit" hypothesis of fatty liver disease. Free Radic Biol Med (2009) 1.01
How can we use our knowledge of alcohol-tobacco interactions to reduce alcohol use? Annu Rev Clin Psychol (2012) 1.01
Smoke-free policies in drinking venues predict transitions in alcohol use disorders in a longitudinal U.S. sample. Drug Alcohol Depend (2012) 0.99
Novel interactions of mitochondria and reactive oxygen/nitrogen species in alcohol mediated liver disease. World J Gastroenterol (2007) 0.99
Genetic polymorphisms of glutathione S-transferase genes GSTM1, GSTT1 and risk of hepatocellular carcinoma. PLoS One (2012) 0.99
Comprehensive analysis of common serum liver enzymes as prospective predictors of hepatocellular carcinoma in HBV patients. PLoS One (2012) 0.99
Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors. World J Gastroenterol (2014) 0.97
Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model. PLoS One (2013) 0.96
Combined effect of socioeconomic status, viral hepatitis, and lifestyles on hepatocelluar carcinoma risk in Korea. Br J Cancer (2010) 0.95
Surveillance for hepatocellular carcinoma in chronic liver disease: evidence and controversies. World J Gastroenterol (2013) 0.94
Non-viral factors contributing to hepatocellular carcinoma. World J Hepatol (2013) 0.93
Convergent mechanisms for dysregulation of mitochondrial quality control in metabolic disease: implications for mitochondrial therapeutics. Biochem Soc Trans (2013) 0.93
Green tea consumption, inflammation and the risk of primary hepatocellular carcinoma in a Chinese population. Cancer Epidemiol (2011) 0.92
New advances in hepatocellular carcinoma. World J Hepatol (2016) 0.91
Prepregnancy body mass index, smoking during pregnancy, and infant birth weight. Ann Epidemiol (2011) 0.90
Prognostic impact of underlying liver fibrosis and cirrhosis after curative resection of hepatocellular carcinoma. World J Surg (2010) 0.89
Body mass index is associated with age-at-onset of HCV-infected hepatocellular carcinoma patients. World J Gastroenterol (2011) 0.88
Relationship between XRCC1 and XPD polymorphisms and the risk of the development of hepatocellular carcinoma: A case-control study. Exp Ther Med (2012) 0.88
Mitochondrial-nuclear genome interactions in non-alcoholic fatty liver disease in mice. Biochem J (2014) 0.87
Smokers report greater demand for alcohol on a behavioral economic purchase task. J Stud Alcohol Drugs (2013) 0.86
Smoke-free bar policies and smokers' alcohol consumption: findings from the International Tobacco Control Four Country Survey. Drug Alcohol Depend (2012) 0.86
Hepatocellular carcinoma in Asia: Prevention strategy and planning. World J Hepatol (2015) 0.85
Risk factors for hepatocellular carcinoma in India. J Clin Exp Hepatol (2014) 0.85
Impact of cigarette smoking on outcome of hepatocellular carcinoma after surgery in patients with hepatitis B. PLoS One (2014) 0.84
Total and high molecular weight adiponectin and hepatocellular carcinoma with HCV infection. PLoS One (2011) 0.84
Smoking is not associated with nonalcoholic fatty liver disease. World J Gastroenterol (2006) 0.84
hOGG1 Ser326Cys polymorphism and risk of hepatocellular carcinoma among East Asians: a meta-analysis. PLoS One (2013) 0.83
Evolving therapies in the treatment of hepatocellular carcinoma. Biologics (2008) 0.83
The role for estrogen receptor-alpha and prolactin receptor in sex-dependent DEN-induced liver tumorigenesis. Carcinogenesis (2011) 0.83
Mechanisms for nicotine in the development and progression of gastrointestinal cancers. Transl Gastrointest Cancer (2012) 0.83
Familial correlations of onset age of hepatocellular carcinoma: a population-based case-control family study. PLoS One (2014) 0.83
Symptom management in hepatocellular carcinoma. Clin J Oncol Nurs (2008) 0.83
Interaction between alcohol drinking and obesity in relation to colorectal cancer risk: a case-control study in Newfoundland and Labrador, Canada. BMC Public Health (2012) 0.82
Design of a randomized controlled trial for multiple cancer risk behaviors among Spanish-speaking Mexican-origin smokers. BMC Public Health (2013) 0.82
Prognosis of patients with hepatocellular carcinoma and hypersplenism after surgery: a single-center experience from the People's Republic of China. Onco Targets Ther (2014) 0.82
NAFLD and liver transplantation: Current burden and expected challenges. J Hepatol (2016) 0.81
Smoking and hepatocellular carcinoma mortality. Exp Ther Med (2011) 0.81
Longitudinal associations between smoking cessation medications and alcohol consumption among smokers in the International Tobacco Control Four Country survey. Alcohol Clin Exp Res (2012) 0.81
Hepatitis B virus infection, diabetes mellitus, and their synergism for cholangiocarcinoma development: a case-control study in Korea. World J Gastroenterol (2015) 0.81
Multiplicative synergistic risk of hepatocellular carcinoma development among hepatitis B and C co-infected subjects in HBV endemic area: a community-based cohort study. BMC Cancer (2012) 0.80
Canadian trends in liver cancer: a brief clinical and epidemiologic overview. Curr Oncol (2013) 0.80
Risk factors of cryptogenic hepatocellular carcinoma in patients with low body mass index or without metabolic syndrome. Korean J Intern Med (2012) 0.80
Nonalcoholic fatty liver disease in a district general hospital: clinical presentation and risk factors. Hepatol Int (2008) 0.80
Imaging of HCC-Current State of the Art. Diagnostics (Basel) (2015) 0.79
Multidisciplinary perspective of hepatocellular carcinoma: A Pacific Northwest experience. World J Hepatol (2015) 0.79
Lentivirus-Mediated siRNA Targeting ER-α Inhibits Tumorigenesis and Induces Apoptosis in Hepatocarcinoma Cells. Biomed Res Int (2015) 0.79
Obesity, but not ethanol, promotes tumor incidence and progression in a mouse model of hepatocellular carcinoma in vivo. Surg Endosc (2013) 0.78
Tissue diagnosis of hepatocellular carcinoma. J Clin Exp Hepatol (2014) 0.78
Increasing incidence in liver cancer in Canada, 1972-2006: Age-period-cohort analysis. J Gastrointest Oncol (2011) 0.78
Adaptation of a counseling intervention to address multiple cancer risk factors among overweight/obese Latino smokers. Health Educ Behav (2014) 0.78
Smoking, posttraumatic stress disorder, and alcohol use disorders in a nationally representative sample of Australian men and women. Drug Alcohol Depend (2015) 0.77
A review of epidemiologic research on smoking behavior among persons with alcohol and illicit substance use disorders. Prev Med (2016) 0.77
Systematic analyses and comprehensive field synopsis of genetic association studies in hepatocellular carcinoma. Oncotarget (2016) 0.77
Mechanisms linking socioeconomic disadvantage and BMI in smokers. Am J Health Behav (2013) 0.77
Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int (2017) 0.77
Are alcohol, tobacco and obesity genuine risk factors for hepatocellular carcinoma? J Hepatol (2005) 0.76
Development and Internal Validation of a Model for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis. J Clin Gastroenterol (2016) 0.76
Genetic polymorphism of the human organic solute carrier protein 1 (hOSCP1) gene in Japanese patients with non-viral liver carcinoma. Meta Gene (2014) 0.76
A preliminary study on the effect of combined nicotine replacement therapy on alcohol responses and alcohol self-administration. Am J Addict (2013) 0.76
β-catenin mutation is correlated with a favorable prognosis in patients with hepatocellular carcinoma. Mol Clin Oncol (2015) 0.76
Association between the C.1161G>A and C.1779C>G genetic variants of XRCC1 gene and hepatocellular carcinoma risk in Chinese population. Int J Biol Sci (2013) 0.75
Evaluating the Influence of Side Stream Cigarette Smoke at an Early Stage of Non-Alcoholic Steatohepatitis Progression in Mice. Toxicol Res (2017) 0.75
Medical Care of the Patient With Compensated Cirrhosis. Gastroenterol Hepatol (N Y) (2006) 0.75
Chronic Intake of Japanese Sake Mediates Radiation-Induced Metabolic Alterations in Mouse Liver. PLoS One (2016) 0.75
Smoking Habit in Severe Obese after bariatric procedures. Tob Induc Dis (2015) 0.75
Psychopharmacology of Tobacco and Alcohol Comorbidity: a Review of Current Evidence. Curr Addict Rep (2017) 0.75
Associations between single-nucleotide polymorphisms of human exonuclease 1 and the risk of hepatocellular carcinoma. Oncotarget (2016) 0.75
Association of VEGFA polymorphisms with susceptibility and clinical outcome of hepatocellular carcinoma in a Chinese Han population. Oncotarget (2017) 0.75
Relationships between cell cycle pathway gene polymorphisms and risk of hepatocellular carcinoma. World J Gastroenterol (2016) 0.75
Chronic Exposure to Low Doses of Dioxin Promotes Liver Fibrosis Development in the C57BL6/J Diet-Induced Obesity Mouse Model. Environ Health Perspect (2016) 0.75
Family history of hepatocellulcar carcinoma is not associated with its patients' prognosis after hepatectomy. World J Surg Oncol (2013) 0.75
Perspectives of Mexican-origin smokers on healthy eating and physical activity. Health Educ Res (2016) 0.75
Gender Differences in the Life Concerns of Persons Seeking Alcohol Detoxification. J Subst Abuse Treat (2015) 0.75
Association study of single nucleotide polymorphisms in XRCC1 gene with risk of hepatocellular carcinoma in Chinese Han population. Biomed Res Int (2013) 0.75
Current Proceedings in the Molecular Dissection of Hepatocellular Adenomas: Review and Hands-on Guide for Diagnosis. Int J Mol Sci (2015) 0.75
HapMap-based study of CIP2A gene polymorphisms and HCC susceptibility. Oncol Lett (2012) 0.75
Diagnostic Imaging of Hepatocellular Carcinoma - A Pictorial Essay. Curr Med Imaging Rev (2017) 0.75
Chemotherapy for Hepatocellular Carcinoma: Current Evidence and Future Perspectives. J Clin Transl Hepatol (2017) 0.75
Implication of the Hedgehog pathway in hepatocellular carcinoma. World J Gastroenterol (2017) 0.75
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology (2003) 16.40
Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med (2002) 11.38
Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology (2005) 10.66
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med (2006) 7.35
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med (2006) 5.65
Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology (2008) 5.45
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology (2005) 3.95
Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology (2009) 3.88
Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology (2006) 3.85
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology (2009) 3.50
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol (2013) 3.41
Screening for Wilson disease in acute liver failure: a comparison of currently available diagnostic tests. Hepatology (2008) 3.04
NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology (2002) 2.96
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol (2010) 2.96
GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol (2005) 2.70
Hepatic fat fraction: MR imaging for quantitative measurement and display--early experience. Radiology (2005) 2.69
Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology (2011) 2.64
Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl (2005) 2.63
Endoscopic Transpapillary Gallbladder Stent Placement Is Safe and Effective in High-Risk Patients Without Cirrhosis. Dig Dis Sci (2014) 2.62
Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev (2012) 2.57
Hospital readmissions among patients with decompensated cirrhosis. Am J Gastroenterol (2011) 2.49
The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis. Gastrointest Endosc (2006) 2.43
Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology (2010) 2.30
Outcomes of living donor liver transplantation for acute liver failure: the adult-to-adult living donor liver transplantation cohort study. Liver Transpl (2008) 2.30
Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology (2011) 2.25
Hepatitis B therapy. Nat Rev Gastroenterol Hepatol (2011) 2.23
Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med (2007) 2.17
Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology (2007) 2.11
Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology (2003) 2.05
CD73 (ecto-5'-nucleotidase) hepatocyte levels differ across mouse strains and contribute to mallory-denk body formation. Hepatology (2013) 2.04
Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol (2005) 2.04
One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol (2005) 2.04
Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology (2008) 2.02
Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology (2011) 2.01
Lymphotoxin regulates commensal responses to enable diet-induced obesity. Nat Immunol (2012) 1.99
Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology (2011) 1.98
Searching for a needle in a haystack: use of ICD-9-CM codes in drug-induced liver injury. Am J Gastroenterol (2007) 1.98
Body fat composition assessment using analytic morphomics predicts infectious complications after bowel resection in Crohn's disease. Inflamm Bowel Dis (2015) 1.97
Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology (2005) 1.97
Modified Charlson comorbidity index for predicting survival after liver transplantation. Liver Transpl (2007) 1.96
Vancomycin-resistant enterococcal colonization and infection in liver transplant candidates and recipients: a prospective surveillance study. Clin Infect Dis (2005) 1.93
Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD. Am J Gastroenterol (2006) 1.91
Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology (2015) 1.87
Fulminant hepatitis A virus infection in the United States: Incidence, prognosis, and outcomes. Hepatology (2006) 1.83
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology (2014) 1.83
Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology (2013) 1.81
Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology (2009) 1.80
Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut (2010) 1.78
Liver transplantation for erythropoietic protoporphyria liver disease. Liver Transpl (2005) 1.76
Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology (2006) 1.73
Energy determinants GAPDH and NDPK act as genetic modifiers for hepatocyte inclusion formation. J Cell Biol (2011) 1.72
DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. J Hepatol (2008) 1.71
Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark (2007) 1.65
Mechanisms of drug-induced liver injury: from bedside to bench. Nat Rev Gastroenterol Hepatol (2011) 1.65
Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl (2007) 1.61
Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients. Liver Transpl (2006) 1.55
Patient knowledge about disease self-management in cirrhosis. Am J Gastroenterol (2013) 1.55
Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology (2008) 1.53
XIAP Is a copper binding protein deregulated in Wilson's disease and other copper toxicosis disorders. Mol Cell (2006) 1.50
Renal outcomes after liver transplantation in the model for end-stage liver disease era. Liver Transpl (2009) 1.49
Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transpl (2005) 1.47
Liver transplantation outcomes among Caucasians, Asian Americans, and African Americans with hepatitis B. Liver Transpl (2009) 1.46
Patient involvement in healthcare is associated with higher rates of surveillance for hepatocellular carcinoma. J Clin Gastroenterol (2011) 1.46
Burden of cirrhosis on older Americans and their families: analysis of the health and retirement study. Hepatology (2012) 1.44
Improved post-transplant survival in the United States for patients with cholangiocarcinoma after 2000. Dig Dis Sci (2013) 1.43
Machine learning algorithms outperform conventional regression models in predicting development of hepatocellular carcinoma. Am J Gastroenterol (2013) 1.39
Transpapillary Gallbladder Stents Can Stabilize or Improve Decompensated Cirrhosis in Patients Awaiting Liver Transplantation. J Clin Gastroenterol (2015) 1.39
Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol (2006) 1.38
Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology (2015) 1.36
A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology (2011) 1.33
An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data. Liver Transpl (2009) 1.31